The Chinese STEMI PPCI Registry (CSPR)

NCT ID: NCT04996901

Last Updated: 2021-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5594 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-22

Study Completion Date

2021-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop a risk score to predict the risks of in-hospital major adverse cardiac events in ST-segment elevation myocardial infarction patients treated by primary percutaneous coronary intervention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The CSPR trial is an observational clinical trial to derive and validate a readily useable risk score to identify patients at high risk of in-hospital major adverse cardiac events in 5594 patients presenting with a ST-segment elevation myocardial infarction and treated by primary percutaneous coronary intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ST-segment Elevation Myocardial Infarction (STEMI)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

derivation cohort

Data from Renmin Hospital of Wuhan University, The First College of Clinical Medical Science, China Three Gorges University, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Xiangyang No.1 People's Hospital,and Wuhan Third Hospital will be used as a derivation cohort.

no intervention

Intervention Type OTHER

no intervention

validation cohort

Data from The First Affiliated Hospital of Dalian Medical University and Jiangxi Provincial People's Hopital will be used as a derivation cohort.

no intervention

Intervention Type OTHER

no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention

no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age≥18
2. ST-segment elevation myocardial infarction was defined according to the universal definition of myocardial infarction
3. STEMI treated by pPCI

Exclusion Criteria

1. Patient with heart failure in admission
2. STEMI with symptom-onset-to-balloon time\>24h
3. pPCI was not successful or only underwent coronary angiography
4. Killip class ≥II in admission
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The First College of Clinical Medical Science, China Three Gorges University

UNKNOWN

Sponsor Role collaborator

The First Affiliated Hospital of Dalian Medical University

OTHER

Sponsor Role collaborator

Jiangxi Provincial People's Hopital

OTHER

Sponsor Role collaborator

The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture

OTHER

Sponsor Role collaborator

Xiangyang No.1 People's Hospital

OTHER

Sponsor Role collaborator

Wuhan Third Hospital

OTHER

Sponsor Role collaborator

Renmin Hospital of Wuhan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Liwei Cheng

Role: STUDY_DIRECTOR

Renmin Hospital of Wuhan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Renmin Hospital of Wuhan university

Wuhan, Hubei, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Xu J, Luo D, Lei Y, Hu Z, Tian H, Chen X, Zhou W, Li M, Liu S, Jin X, Wang Y, Zhang B, Zhou Q, Chen J. Correlation between abnormal microvascular perfusion and quantitative flow ratio after primary PCI in patients with STEMI. Int J Cardiol. 2025 Mar 1;422:132949. doi: 10.1016/j.ijcard.2024.132949. Epub 2024 Dec 31.

Reference Type DERIVED
PMID: 39746473 (View on PubMed)

Wang H, Yang Y, Zeng P, Huang R, Cai X, Shao L, Liu F, Lei Y, Li D, Fan Z, Yang J, Zhang J, Yang J. Association between Systemic Immune-Inflammation Index (SII) and New-Onset In-Hospital Heart Failure in Patients with STEMI after Primary PCI. Rev Cardiovasc Med. 2024 Oct 24;25(10):382. doi: 10.31083/j.rcm2510382. eCollection 2024 Oct.

Reference Type DERIVED
PMID: 39484131 (View on PubMed)

Hu Z, Luo D, Zhou WJ, Xu CW, Chen XZ, Zhang BF, Jin X, Wang Y, Zhang J, Wu H, Liu FY, Lei YH, Li DS, Cai XY, Jiang H, Chen J. Association between admission blood pressure and spontaneous reperfusion and long-term prognosis in STEMI patients: an observational and multicenter study. BMC Cardiovasc Disord. 2024 Sep 18;24(1):500. doi: 10.1186/s12872-024-04168-4.

Reference Type DERIVED
PMID: 39294617 (View on PubMed)

Luo D, Huang R, Wang X, Zhang J, Cai X, Liu F, Lei Y, Li D, Zhou W, Xu C, Huang B, Jiang H, Chen J. INTRA-AORTIC BALLOON PUMP REDUCES 30-DAY MORTALITY IN EARLY-STAGE CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION ACCORDING TO SCAI CLASSIFICATION. Shock. 2023 Sep 1;60(3):385-391. doi: 10.1097/SHK.0000000000002184. Epub 2023 Aug 4.

Reference Type DERIVED
PMID: 37548623 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

958374

Identifier Type: -

Identifier Source: org_study_id